Registration Dossier
Registration Dossier
Data platform availability banner - registered substances factsheets
Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.
The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.
Diss Factsheets
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 611-390-2 | CAS number: 56467-43-7
- Life Cycle description
- Uses advised against
- Endpoint summary
- Appearance / physical state / colour
- Melting point / freezing point
- Boiling point
- Density
- Particle size distribution (Granulometry)
- Vapour pressure
- Partition coefficient
- Water solubility
- Solubility in organic solvents / fat solubility
- Surface tension
- Flash point
- Auto flammability
- Flammability
- Explosiveness
- Oxidising properties
- Oxidation reduction potential
- Stability in organic solvents and identity of relevant degradation products
- Storage stability and reactivity towards container material
- Stability: thermal, sunlight, metals
- pH
- Dissociation constant
- Viscosity
- Additional physico-chemical information
- Additional physico-chemical properties of nanomaterials
- Nanomaterial agglomeration / aggregation
- Nanomaterial crystalline phase
- Nanomaterial crystallite and grain size
- Nanomaterial aspect ratio / shape
- Nanomaterial specific surface area
- Nanomaterial Zeta potential
- Nanomaterial surface chemistry
- Nanomaterial dustiness
- Nanomaterial porosity
- Nanomaterial pour density
- Nanomaterial photocatalytic activity
- Nanomaterial radical formation potential
- Nanomaterial catalytic activity
- Endpoint summary
- Stability
- Biodegradation
- Bioaccumulation
- Transport and distribution
- Environmental data
- Additional information on environmental fate and behaviour
- Ecotoxicological Summary
- Aquatic toxicity
- Endpoint summary
- Short-term toxicity to fish
- Long-term toxicity to fish
- Short-term toxicity to aquatic invertebrates
- Long-term toxicity to aquatic invertebrates
- Toxicity to aquatic algae and cyanobacteria
- Toxicity to aquatic plants other than algae
- Toxicity to microorganisms
- Endocrine disrupter testing in aquatic vertebrates – in vivo
- Toxicity to other aquatic organisms
- Sediment toxicity
- Terrestrial toxicity
- Biological effects monitoring
- Biotransformation and kinetics
- Additional ecotoxological information
- Toxicological Summary
- Toxicokinetics, metabolism and distribution
- Acute Toxicity
- Irritation / corrosion
- Sensitisation
- Repeated dose toxicity
- Genetic toxicity
- Carcinogenicity
- Toxicity to reproduction
- Specific investigations
- Exposure related observations in humans
- Toxic effects on livestock and pets
- Additional toxicological data
Endpoint summary
Administrative data
Link to relevant study record(s)
Description of key information
No experimental data on absorption, distribution, metabolism and excretion of BPMA are available.
Qualitative information on toxicokinetic behaviour can be derived taking into account the information on the physico-chemical properties of the compound as well as data obtained in a basic data set.
Absorption
Based on physico-chemical properties, oral absorption by passive diffusion is plausible. Based on physico-chemical properties, dermal absorption is plausible. Based on low vapour pressure, inhalatory absorption is considered as not relevant due to low exposure.
Distribution
Physico-chemical properties of B
NMA indicates a moderate distribution in the body.
Bioaccumulation
Due to the well-known metabolism of methacrylate esters the bioaccumulation potential is considered as negliable.
Metabolism of Methacrylic esters
Ester hydrolysis by carboxylesterases has been established as the primary step in the metabolism of methacrylate esters. Methacrylic acid as one primary metabolite of BNMA is subsequently cleared predominantly via the liver (valine pathway and the TCA (TriCarboxylic Acid) cycle, respectively).
Excretion
The majority of the methacrylic metabolite MAA is exhaled as CO2.
Key value for chemical safety assessment
- Bioaccumulation potential:
- no bioaccumulation potential
- Absorption rate - oral (%):
- 50
- Absorption rate - dermal (%):
- 50
- Absorption rate - inhalation (%):
- 100
Additional information
Toxicokinetic Statement of 4-Benzoylphenyl methacrylate (BPMA)
General
No experimental data on absorption, distribution, metabolism and excretion of BPMA are available.
According to REACH, the human health hazard assessment shall consider the toxicokinetic profile (Annex I). However, generation of new data is not required as the assessment of the toxicokinetic behaviour of the substance should be performed to the extent that can be derived from the relevant available information (REACH Annex VIII, 8.8.1).
Qualitative information on toxicokinetic behaviour can be derived taking into account the information on the physico-chemical properties of the compound as well as data obtained in a basic data set.
Absorption
The observation of systemic toxicity following exposure by any route is an indication for substance absorption; however, this will not provide any quantitative information. Relevant acute oral toxicity, skin sensitisation and irritation as well as toxicity after repeated oral dosing was not observed with BPMA. No information on acute dermal or inhalatory toxicity is available. Thus, data from existing toxicity studies do not give any indication for the extend of absorption.
To be absorbed, the substance has to cross biological membranes, either by active transport mechanisms or - as being the case for most compounds - by passive diffusion. The latter is dependent on compound properties such as molecular weight, lipophilicity, and water solubility. In general, low molecular weight (MW ≤ 500) and moderate lipophilicity (log P values of - 1 to + 4) are favourable for membrane penetration and thus absorption. The molecular weight of BNMA is relatively moderate with 266 g/mol, favouring oral absorption of the compound; in addition, the substance is moderately lipophilic (log of 3.6) and water solubility is given (4 mg/L) indicating that absorption by passive diffusion is plausible (ECHA Guidance R.7c, 2017; Chapter R7.12.2.1). As a consequence for rsik assessment and DNEL calculation, the default rate of 50% for oral absorption is considered as plausible (ECHA Guidance R.8, 2012; Chapter R.8.4.2).
Dermal uptake is expected to be moderate at this molecular weight level (< 100: dermal uptake high; > 500: no dermal uptake). For dermal uptake, sufficient water solubility is needed for the partitioning from the stratum corneum into the epidermis. Therefore, at the water solubility level of 1-100 mg/L, dermal uptake is anticipated to be low to moderate. On the other hand the log P of 3.6 allows dermal absorption. As a conclusion, based on the discussed physico-chemical parameters, dermal absorption is considered as plausible and a default value of 50% skin absorption rate can be used for risk assessment (ECHA references see above).
For respiratory uptake it can be considered that generally liquids would readily diffuse/dissolve into the mucus lining. Thereby, lipophilic substances with moderate log P values (between - 1 and 4) are favourable for absorption directly across the respiratory tract epithelium by passive diffusion. This is given for BPMA with a log P value of 3.6. However, the calculated vapour pressure is low (0.0056 Pa) so that inhalative exposure is not considered as relevant exposure route when compared with oral and dermal exposure. Although respiratory absorption is considered as not plausible, the default value of 100% respiratory absorption rate can be used for risk assessment as a worst case approach (ECHA references see above).
Distribution
Some information or indication on the distribution of the compound in the body might be derived from the available physico-chemical and toxicological data. Once a substance has entered the systemic circulation, its distribution pattern is likely to be similar for all administration routes. However, first pass effects after oral exposure influence the distribution pattern and distribution of metabolites is presumably different to that of the parent compound.
The smaller a molecule, the wider is its distribution throughout the body. The molecular weight of 266 g/mol, the moderate water solubility of BNMA indicates a moderate distribution in the body. Through its lipophilic properties (log P > 0), BNMA is likely to distribute into cells and the intracellular concentration may be higher than extracellular concentration particularly in fatty tissue.
The results of the toxicity studies identified no target organ toxicity (ECHA Guidance R.7c, 2017; Chapter R7.12.2.1).
Bioaccumulation
While the log P of BNMA is between 3 and 4 and thus not indicative for accumulation in fatty tissue ((ECHA Guidance R.7c, 2017; Chapter R7.12.2.1), it can be concluded from the well-known metabolism of methacrylate esters that the bioaccumulation potential is considered as negliable due to the assumed rapid hydrolysis by ubiquitous carboxylesterase enzymes (see below).
Metabolism of Methacrylic esters
Ester hydrolysis by carboxylesterases has been established as the primary step in the metabolism of methacrylate esters. For MMA and other short-chain alkyl-methacrylate mono esters extensive toxicokinetic data are available, for example in the EU Risk Assessment for MMA (2002) as well as the OECD SIAR for short-chain alkyl-methacrylate esters (EMA, n-BMA, i-BMA and 2-EHMA, 2009) which will serve as supportive information for BNMA with a more complex alcohol moiety.
Taken from the OECD SIAR: “The carboxylesterases are a group of non-specific enzymes that are widely distributed throughout the body and are known to show high activity within many tissues and organs, including the liver, blood, GI tract, nasal epithelium and skin (Satoh & Hosokawa, 1998; Junge & Krish, 1975; Bogdanffy et al., 1987; Frederick et al., 1994). Those organs and tissues that play an important role and/or contribute substantially to the primary metabolism of the short-chain, volatile, alkyl-methacrylate esters are the tissues at the primary point of exposure, namely the nasal epithelia and the skin, and systemically, the liver and blood.”
Taken from the EU Risk Assessment on MMA; “Activities of local tissue esterases of the nasal epithelial cells appear to be lower in man than in rodents (Green, 1996 later published as Mainwaring, 2001). Toxicokinetics seem to be similar in man and experimental animal. After arthroplasty using methyl methacrylate-based cements, exhalation of unchanged ester occurs to a greater extent than after i.v., i.p. or oral administration. After oral or parenteral administration methyl methacrylate is further metabolised by physiological pathways with the majority of the administered dose being exhaled as CO2 (Bratt and Hathway, 1977; ICI, 1977a). Conjugation with GSH or NPSH plays a minor role in methyl methacrylate metabolism and only occurs at high tissueconcentrations (McCarthy and Witz, 1991; Elovaara et al., 1983)”.
Taken from the OECD SIAR: “Other short chain alkyl-methacrylate esters, like MMA, are initially hydrolyzed by non-specific carboxylesterases to methacrylic acid and the structurally corresponding alcohol in several tissues (ECETOC 1995, 1996b).
Studies completed after the MMA RA have confirmed that all lower alkyl-methacrylate esters are rapidly hydrolysed by ubiquitous carboxylesterases. First pass (local) hydrolysis of the parent ester has been shown to be significant for all routes of exposure. For example, no parent ester can be measured systemically following skin exposure to EMA and larger esters, as the lower rate of absorption for these esters is within the metabolic capacity of the skin (Jones, 2002). Parent ester will also be effectively hydrolysed within the G.I. tract and within the tissues of the upper respiratory tract (particularly the olfactory tissue). Systemically absorbed parent ester will be effectively removed during the first pass through the liver resulting in their relatively rapid elimination from the body.
Subsequent metabolism of the primary metabolites within the body
Again, taken from the OECD SIAR for methacrylate esters with smaller alkyl alcohol moieties: “Methacrylic acid and the corresponding alcohol are subsequently cleared predominantly via the liver (valine pathway and the TCA (TriCarboxylic Acid) cycle, respectively).”
In terms of MAA, the common metabolite for these esters a comparison of measured blood concentration data after i. v. administration of 10 and 20 mg/kg MAA was made and a simulation based on a one-compartment model shows good agreement (Jones, 2002). Based on that information, the following kinetic parameters were determined from a simultaneous fit of the in vivo data to a one-compartment model with non-linear elimination (Vss = 0.039 L/SRW; Vmax = 19.8 mg/hr x SRW; Km = 20.3 mg/L; SRW: standard rat weight = 250 g) the half-life of MAA in blood was calculated as 1.7 min.
Excretion
The majority of the methacrylic metabolite MAA is exhaled as CO2.
Literature
Bogdanffy MS, Randall HW, Morgan KT (1987). Biochemical quantitation and histochemical localization of carboxylesterase in the nasal passages of the Fischer-344 rat and B6C3F1 mouse. Toxicology and Applied Pharmacology 88: 183-194.
Bratt H, Hathway DE (1977). Fate of methyl methacrylate in rats. Brit. J. Cancer 36, 114-119.
ECHA (2017). Guidance on Information Requirements and Chemical Safety Assessment Chapter R.7c: Endpoint specific guidance v3.0, European Chemicals Agency, ECHA-17-G-11-EN, June 2017.
ECHA (2012). Guidance on Information Requirements and Chemical Safety Assessment Chapter R.8: Characterisation of dose [concentration]-response for human health v2.1, European Chemicals Agency, ECHA-2010-G-19-EN, Nov 2012.
Elovaara E, Kivistoe H, Vainio H (1983). Effects of methyl methacrylate on non-protein thiols and drug metabolizing enzymes in rat liver and kidneys. Arch. Toxicol. 52, 109-121.
European Chemicals Bureau (2002). European Union - Risk Assessment Report on Methyl methacrylate. European Union - Risk Assessment Report, Vol. 22.
Frederick C. B., Udinsky J. R., Finch L (1994). The regional hydrolysis of ethyl acrylate to acrylic acid in the rat nasal cavity. Toxicology letters, 70: 49-56.
Jones O (2002). Using physiologically based pharmacokinetic modelling to predict the pharmacokinetics and toxicity of methacrylate esters. A Thesis submitted to Univ. of Manchester for the degree of Doctor of Philosophy.
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.